Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NS-245 in Healthy Subjects
jRCT2071250086Phase 1Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NS-245 (6 arms), sponsored by Nippon Shinyaku. Primary endpoints: Primary - Pharmacokinetics of NS-245, Primary - Safety of NS-245 and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
NS-245
Beyond the preview
Go deeper on jRCT2071250086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250086.